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Epidemiology literally means ‘‘the study of what is
upon the people.’’ It puts the individual’s condition in
a population context and is the path to disease
prevention. In the first part of this review, important
aspects of epidemiology are discussed. Fundamentals
of epidemiologic research include the measurement
of occurrence of an event (prevalence and incidence)
and the identification of factors that are associated
with this event. The main study designs in observa-
tional studies are cohort, case–control, and cross-
sectional studies, all of which have intrinsic strengths
and limitations. These limitations include a variety of
biases, which can be regrouped into selection bias,
information bias, and confounding. The STROBE
(Strengthening the Reporting of Observational Stu-
dies in Epidemiology) checklist is an important tool to
further improve the reporting and quality of epide-
miologic studies, and it is introduced. In the second
part of this review, practical examples are presented,
illustrating how dermatoepidemiology has contribu-
ted to an improved understanding of skin diseases
and patient care, specifically in the case of melanoma
therapy, serious cutaneous adverse reactions, Lyme
disease, long-term safety of psoralin plus UVA (PUVA),
teratogenicity of isotretinoin, and comorbidities in
psoriasis.
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INTRODUCTION
The term Epidemiology originates from the Greek language
and literally means ‘‘the study of what is upon the people.’’ A
more modern definition is ‘‘the study of the distribution and
determinants of disease frequency in human populations.’’ In
addition, it is ‘‘the branch of medical science dealing with the
control of epidemics,’’ which has an important role in disease
prevention at a population level.
Although there are several specialties within epidemio-
logy, such as molecular and genetic epidemiology,
pharmacoepidemiology (and comparative effectiveness), en-
vironmental epidemiology, and epidemiology of cancer and
infectious diseases, the objective of most epidemiologic
research is to measure the frequency of disease occurrence
(and its trend in time) and/or to obtain a valid and precise
estimate of the effect of a potential cause on the occurrence
of disease (i.e., identification of risk factors). In addition,
epidemiology is the methodological backbone for fields
of public health, evidence-based medicine, and outcome
research. Fundamentally, epidemiologic studies put the
individual’s condition in a population context.
Measure of occurrence
Much of the medical, including the dermatologic, literature is
based on case reports and case series (Glasziou et al., 2004).
These reports are descriptive and may provide interesting
information about diagnostic findings and treatment and/or
prognosis of (rare) diseases. Because the sample of patients
in a case series is unlikely to represent that of all patients with
the condition, the generalizability to other patients may be
limited.
Two measures of the frequency of a disease in a
population are incidence and prevalence (Victora, 1993).
Person-time incidence is simply the number of people
developing a condition in that specified period of time
in a defined population (i.e., new cases). Cumulative
incidence is the proportion of the susceptible population
that develops a condition in a given period of time.
Prevalence refers to the proportion of people with an existing
condition at a given point in time and, therefore, depends
on the incidence and chronicity of the disease. Preva-
lence information is most often helpful when placed in a
population context, such as point prevalence by age and
gender, or with a more specified time period (e.g., lifetime
prevalence).
Many investigators are interested in the likelihood of
developing a condition during an individual’s lifetime in a
certain group. The length of time a person contributes often
varies (e.g., death, moved away, or lost to follow-up) and
must be considered for incidence rates to be accurate (i.e.,
the occurrence of new cases of a disease per unit of person-
time; number of events/100,000 person-years). Incidence
proportion measures the proportion of people in a defined
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population who develop a new disease in a specified time
period, reflecting individual risk.
The age, gender, and race distributions in populations
often differ among regions, and these demographic char-
acteristics are likely to change over time. Therefore,
incidence rates should be calculated with direct standardiza-
tion according to the European, the United States, or the
World Health Organization census data. Direct standardized
incidence rates make it possible to compare disease
incidence rates across different populations and trends
within populations. For example, by adjusting for age and
gender of each country’s population over time, standardiza-
tion allows comparison of melanoma incidence among
European countries and at different time periods (Karim-
Kos et al., 2008).
Measures of effect or association
A factor, which may be behavioral, environmental, ther-
apeutic, or genetic, may be associated with the frequency of a
disease (Rothman et al., 2008). The categorical or continuous
distribution of the factor can be statistically compared among
people with and without the disease to assess the magnitude
of the association and the possible effect of the factor on the
disease outcome. This first and simple approach is called
descriptive statistics and results in a P-value, which only
reflects the likelihood that the observed association is a
chance finding (Altman and Bland, 1995). A significant
P-value shows that the likelihood that the research finding
is a chance finding is o5%; however, it does not provide
information about the strength of the association, nor does it
take the possible impact of other variables into account
(Gardner and Altman, 1986). Other factors that affect the
factor of interest and the outcome (i.e., confounders) may be
unevenly distributed among the cases (e.g., people with a
disease or those who have been exposed) and controls. To
adjust for the effect of confounders on the association of
interest, multivariate models (and stratification) are particu-
larly useful. The type of statistical model used primarily
depends on the distribution of the outcome (binary,
continuous, proportional, or nominal) and whether the
outcome is time dependent (i.e., survival or longitudinal
data) (Katz, 2003). These types of analyses are part of the
inferential statistics that try to infer from the sample data
pertaining to the underlying general populations and provide
risk estimates (e.g., odds ratios, relative risks, coefficients,
hazard ratios) with 95% confidence intervals. The risk
estimate provides insight into the strength of the association
and is statistically significant if the 95% confidence interval
excludes 1 or 0, depending on the type of analysis. It is
important to be aware that these models can only adjust the
observed association for variables in the model (i.e., factors
that have been measured in the study) and that there is always
residual confounding (i.e., the effect of factors unknown or
not included in the analysis). Most epidemiological studies
do not explain more than 30% of the variability of the
association studied, indicating that considerable information
about the causes of the condition is either not known and/or
not entered in the model.
As the interpretation of the (adjusted) risk estimates is not
always straightforward in clinical practice, new concepts
have been developed to better capture the effect of a factor
(e.g., number needed to treat or harm and population
attributable risk) (Manriquez et al., 2007).
Types of epidemiologic studies
The epidemiological study designs comprise both experi-
mental studies, which are beyond the scope of this
commentary, and nonexperimental (observational) studies.
In experimental studies such as randomized clinical trials
(RCTs), the investigator manipulates the exposure by random-
izing the intervention across often relatively small homo-
geneous patient groups. As you move up the pyramid of
evidence (or the hierarchy of study design; Figure 1), the
study design is more rigorous and allows for less bias or
systematic error that may distract an investigator from the
truth. Simultaneously, the amount of available literature
decreases, but increases in its relevance to the clinical setting.
Although RCTs and their meta-analyses provide stronger
clinical evidence than do observational studies, observational
studies may provide unique information about interventions
in large and heterogeneous populations not feasible for RCTs
(Vandenbroucke, 2004) because of ethical considerations
and/or cost. There are different types of observational studies,
including cohort studies, case–control studies, and cross-
sectional studies (Table 1).
In a cohort study, a group of people with a specific
exposure or characteristics, but without the disease of interest
at baseline, are followed up over time (with or without a
reference cohort). In an exposure cohort, the occurrence of
disease can be compared across different levels of exposure.
One of the best-described exposure cohorts in dermatology is
the psoralin plus UVA (PUVA) Follow-up Study that followed
up 1,380 psoriasis patients who had received PUVA therapy
to assess the long-term safety of this treatment (Stern et al.,
1979). Ideally, a reference cohort without the exposure, but
with the disease, runs parallel to the exposed cohort in order
to assess the baseline risk of the cohort members, but these
control cohorts need to be very large and population based.
Meta-
analyses
Cohort studies
Case–control studies
Case series/case reports
Animal research
Systematic
reviews
Randomized
controlled trials
Figure 1. Hierarchy of study design.
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Cohorts can also consist of a heterogeneous group of people
from the general population who have something else in
common other than an exposure: e.g., their profession
(Nurses Health Study I and II), residence (Framingham cohort
and Rotterdam Study), or general physician (UK General
Physician Research Database). Subsequently, comparisons of
disease occurrence are made within the cohort across
subgroups defined by one or more exposures. The power of
cohort studies to provide information on infrequent events is
often limited because the sample sizes of even the largest
existing cohorts may be too small.
Case–control studies are the most commonly conducted
studies to measure the effect of a factor on disease
development, severity, and/or progression. They are particu-
larly useful when a cohort study is too expensive or
cumbersome to conduct (which in real life is often the case,
especially for relatively rare outcomes). When the outcomes
and/or exposures of the study are rare, case–control methods
compare cases (i.e., individuals with the condition of interest)
and controls, who are people without the condition but
thought to be representative of the population from which the
cases arise. The level of exposure to possible causes of the
condition is assessed retrospectively, often using question-
naires or by means of interview in both groups. Subsequently,
in a case–control study, the proportion of cases with a
potential risk factor is compared with the proportion of
controls with the same risk factor. Among the most difficult
challenges of case–control studies are accurate assessment of
exposure data retrospectively (recall bias) and, especially,
identification of adequate controls.
Cross-sectional studies assess an event, which can be the
presence of a disease or risk factor, in a population at one
point in time, irrespective of the presence and duration of the
disease. This study can only be used to estimate the disease
prevalence if it includes all individuals in a population or a
representative sample of that population; otherwise, it
provides a biased assessment. Therefore, a clear definition
of the study population and a high response (or capture) rate
is required. Because cross-sectional studies are often used in
restricted patient populations (e.g., those visiting a dermatol-
ogy department) or as they do not sample a high proportion of
the population, their findings may not be representative of the
patients in the general population. This observational study
design seems quite simple; however, it is likely to suffer from
sampling bias, length-time bias (diseases with longer duration
are overrepresented compared with those with shorter
duration), and often has difficulty determining the order of
events, which is important in determining the likelihood of
causality.
Association versus causality
One of the strengths of clinical epidemiology is its capacity to
generate hypotheses that can be further evaluated in
observational studies, RCTs, and basic science research. An
inability to differentiate definitively between a simple
association and a true causal relationship is the intrinsic
limitation of epidemiology (Hill, 1965). Several observations
that are part of the nine criteria of Hill (1965) support an
observed association representing a causal hypothesis: (1)
consistency in observational and experimental studies; (2) the
cause precedes the effect in time (temporality); (3) the
observation of an exposure–response relationship, increasing
levels of exposure increases or decreases the likelihood of the
outcome as expected; and (4) biological plausibility of the
Table 1. Description of the most common types of observational studies
Cohort (Incidence, Longitudinal Study) Study: An analytical, observational study, based on data, usually primary, from a follow-up period of a group in
which some have had, have, or will have the exposure of interest, to determine the association between that exposure and an outcome. Cohort studies are
susceptible to bias by differential loss to follow-up, the lack of control over risk assignment and thus confounder symmetry, and the potential for zero time
bias when the cohort is assembled. Prospective cohort studies are stronger than retrospective cohort studies and case–control studies, but are also more
expensive. Because of their observational nature, cohort studies do not provide empirical evidence that is as strong as that provided by properly executed
randomized controlled clinical trials.
Case–Control Study: A retrospective, analytical, observational study often based on data in which the proportion of cases with a potential risk factor are
compared with the proportion of controls (individuals without the disease) with the same risk factor. The common association measure for a case–control
study is the odds ratio. These studies are commonly used for initial, inexpensive evaluation of risk factors and are particularly useful for rare conditions or for
risk factors with long induction periods. This study type has the potential for many forms of bias, especially the selection of appropriate controls is
challenging.
Cross-Sectional (Prevalence Study) Study: A descriptive study of the relationship between diseases and other factors at one point in time (usually) in a defined
population. Cross-sectional studies lack any information on timing of exposure and outcome relationships and include only prevalent cases.
Ecologic (Aggregate) Study: An observational analytical study based on aggregated secondary data. Aggregate data on risk factors and disease prevalence
from different population groups are compared to identify associations. Because all data are aggregate at the group level, relationships at the individual level
cannot be empirically determined but are rather inferred from the group level. Thus, this type of study provides weak evidence for a causal relationship at the
individual level.
Case Series: A descriptive, observational study of a series of cases, typically describing the manifestations, clinical course, and prognosis of a condition. A
case series provides weak empirical evidence because of the lack of a control group. Case series are best used for the generation of hypotheses that can be
evaluated in additional studies. The case series is among the most common study type in the clinical literature.
Case Report: Anecdotal evidence. A description of a single case, typically describing the manifestations, clinical course, and prognosis of that case. Because
of the wide range of natural biologic variability in these aspects, a single case report provides little empirical evidence to the clinician. They do describe how
others diagnosed and treated the condition and what the clinical outcome was.
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basic science supports the causal relationship. This implies
that the results of observational studies should be interpreted
with caution, which requires some modesty on the part of
researchers.
Biases
Because epidemiology is based on observing people (i.e.,
what we all do daily), every individual is an amateur
epidemiologist. However, this does not make it an easy
science. It is rather a science that people can easily relate to
and is, therefore, interesting to the media and the lay public.
Because the study results are overinterpreted, counterintui-
tive, or contradict previous observations, the status of
epidemiology and biostatistics as a rigorous science is
sometimes questioned. For an optimal interpretation of
observational studies, one needs to understand the under-
lying concepts and study designs of epidemiology, the
limitations of epidemiology (e.g., association vs. causality),
the implications of the results, and potential biases (Sackett,
1979; Greenland and Lash, 2008).
A good informative study is accurate and precise (i.e., little
random error and, thus, reproducible). Adequate sample size,
limited bias, and low systematic error are key to accurate
results. There are a variety of possible biases depending on
the study design and objectives, but they can be regrouped
into three main types of biases: selection bias, information
bias, and confounding.
Selection bias is about who is and who is not in the study
population. The selection of the study population may
depend on the outcome or the exposure in a case–control
or cohort study, respectively. Classical examples of selection
bias are ‘‘healthy worker effect,’’ referral bias, and observer
bias. Avoiding selection bias makes optimal choice of
controls in a case–control study important and challenging.
A good study design can reduce selection bias; however, if
present, selection bias cannot be corrected for after the data
have been collected.
Information bias is also referred to as misclassification bias
and represents a measurement error. In nondifferential
misclassification bias, the misclassification is random and
has the same error rate in all study subjects (i.e., the error
does not differentiate between cases and controls). This bias
often dilutes the association toward the null value, resulting
in an underestimation. In differential misclassification bias,
the probability of being misclassified differs between the
study groups and may, therefore, result in an overestimation
or underestimation of the true extent of the association. An
example of differential misclassification bias is recall bias
(e.g., skin cancer patients are more likely to recall severe
sunburns in the past compared with controls). In contrast to
the differential misclassification bias, the nondifferential
variant cannot be corrected for in the analyses. Blinding
both cases and controls to the study hypothesis may reduce
the extent of information bias.
Confounding bias occurs when the observed association
is (in part) attributable to other variables. A confounder
is associated with both the outcome and the exposure
and, therefore, affects their association. The remedy for
confounding is restriction of the study population (clear
eligibility criteria for cases and controls that consider
potential confounders), matching, and randomization. At
the level of analysis, confounding can be adjusted for by
stratification of the analyses (e.g., if gender is a confounder,
the results for men and women should be presented
separately) or by using multivariate models. Confounding
by indication occurs when the indication is independently
associated with the exposure and the outcome, and it often
results in overestimation (e.g., people have been prescribed a
drug for an indication that is also a predictor for the disease
being studied). Confounding should be differentiated from
effect modification and interaction, which are in the causal
pathway of exposure and outcome. The latter cannot simply
be adjusted for in multivariate models and may require
stratification of the analysis.
STROBE (STRENGTHENING THE REPORTING OF
OBSERVATIONAL STUDIES IN EPIDEMIOLOGY)
A research report should clearly describe what was planned,
what was done, what was found, and the conclusions drawn.
In the past 15 years, approximately 10 guidelines and
practical checklists, often with intriguing acronyms, have
been developed to improve the quality of a variety of study
designs. In 2007, a diverse group of more than 30 experts
invented the STROBE checklist (von Elm et al., 2007; Nijsten
et al., 2008). Its goal was to improve the quality of reports of
observational studies including case–control, cohort, and
cross-sectional studies (Table 2). Alongside the STROBE
checklist, a freely accessible comprehensive explanatory
document provides detailed definitions of epidemiological
terms, the controversies surrounding the items, and sugges-
tions on how to deal with the items. For each item on the
checklist, practical examples derived from the published
literature are given to illustrate their importance. Although
observational research is heterogeneous, STROBE provides
clear recommendations for reporting observational research
and—indirectly—for conducting this type of research.
Recently, a working group from the EDEN (European
Dermato-Epidemiology Network) reviewed 138 observa-
tional studies (published between 2005 and 2007, in the
period before STROBE) from five top dermatological journals
and confirmed the need to improve the quality of reporting
(Langan et al., 2010). They recommended that dermatology
journals adopt the STROBE criteria.
EXAMPLES OF CONTRIBUTION
In the following section, several practical examples are given
on how epidemiology has contributed to a better under-
standing of the etiology, therapy, and/or prevention of skin
diseases.
From UV exposure to melanoma therapy
UV exposure is associated with a higher melanoma risk. It
took multiple epidemiological studies with a variety of study
designs over several decades to establish this ‘‘common
knowledge’’: (1) excessive, intermittent, and chronic sun expo-
sure at different age periods affects melanoma development;
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Table 2. STROBE Statement—checklist of items that should be included in reports of observational studies
Item no. Recommendation
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract
(b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported
Objectives 3 State specific objectives, including any prespecified hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data
collection
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe
methods of follow-up
Case–control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control
selection. Give the rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed
Case–control study—For matched studies, give matching criteria and the number of controls per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic
criteria, if applicable
Data sources/measurement 81 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were
chosen and why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Case–control study—If applicable, explain how matching of cases and controls was addressed
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy
(e) Describe any sensitivity analyses
Results
Participants 131 (a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined
for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed
(b) Give reasons for nonparticipation at each stage
(c) Consider use of a flow diagram
Descriptive data 141 (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and
potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—Summarize follow-up time (e.g., average and total amount)
Outcome data 151 Cohort study—Report numbers of outcome events or summary measures over time
Case–control study—Report numbers in each exposure category, or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95%
confidence interval). Make clear which confounders were adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses 17 Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses
Discussion
Key results 18 Summarize key results with reference to study objectives
Table 2 continued on the following page
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(2) people with a fair pigment status (hair, skin, and eye color)
are at increased risk; (3) melanoma rates are higher at locations
with lower latitude, especially among Caucasian immigrants;
(4) nevi (which may be precursors of melanoma) are induced
by higher levels of solar exposure; (5) polymorphisms in
several pigment-related genes are associated with melanoma
risk; and (6) patients with impaired DNA repair of UV-induced
damage are at a high risk of developing melanoma. Since the
1980s, sun exposure has been accepted as the most important
risk factor for developing cutaneous malignancies. In 1992, the
WHO (World Health Organization) declared the INTERSUN
goals that included reducing UV exposure and increasing
sun awareness (http://www.who.int/uv/intersunprogramme/en/).
Information on the hazards of excessive UV exposure has been
included in preventive public health campaigns aimed at the
general population to decrease the incidence of cancer.
In 2003, a case–case study using Australian cancer registry
data demonstrated that patients with melanoma at chroni-
cally exposed sites (such as the head and neck) and with
lentigo maligna melanoma had significantly more solar
keratosis and less nevi compared with those with a
melanoma on the trunk (Whiteman et al., 2003). They
concluded that ‘‘cutaneous melanomas may arise through
two pathways, one associated with melanocyte proliferation
and the other with chronic exposure to sunlight.’’ In the same
year, a genetic cohort study also focusing on differences
within the heterogeneous group of melanomas showed that
BRAF mutations were significantly more common in mela-
nomas occurring on skin intermittently exposed to UV
compared with tumors located at chronically exposed and
nonexposed sites (Maldonado et al., 2003). After 7 years, the
first phase I dose escalation trial of an orally available
inhibitor of mutated BRAF was published and showed partial/
complete remission in 81% of the 51 patients (Flaherty et al.,
2010). A recent phase III RCT showed that vemurafenib had a
response rate of 48% in patients with metastatic melanoma
with BRAF mutations (Chapman et al., 2011).
The melanoma example clearly demonstrates the impor-
tance of observational studies in identifying causative
factors in carcinogenesis, which is pivotal in public health
prevention campaigns. The combination of epidemiological
and clinical observations with other fields of science such
as molecular biology and genetics has resulted in a true
therapeutic advancement in melanoma.
Identification of culprit drugs and high-risk people in severe
skin reactions
Severe cutaneous adverse reactions (SCAR) to medications
may be significant and life threatening but are, fortunately,
infrequent. Case–control epidemiologic studies have a key
role in establishing the relative risks of different medications
in causing Stevens–Johnson syndrome and toxic epidermal
necrolysis. Previously, information about drugs as a cause
of SCAR was largely based on case reports, which usually
lacked sufficient information to assess causality with con-
fidence and which provided little insight into the absolute or
relative risk of various medications.
Because these reactions are relatively rare, drug safety
surveillance over a large population (phase IV studies)
is required to ascertain a sufficient number of cases. An
international collaboration was organized in the late 1980s
to study the association of specific medication with Stevens–-
Johnson syndrome and toxic epidermal necrolysis. The
researchers developed criteria for cases and trained investi-
gators at cooperating hospitals in the ascertainment of cases
and collection of comprehensive data on cases and controls
(Bastuji-Garin et al., 1993). Only cases judged by an expert
panel blinded to drug exposures were considered as validated
cases and included in the analysis. The study provided
a list of culprit drugs and robust estimates of the relative risks
of Stevens–Johnson syndrome and toxic epidermal necro-
lysis in association with commonly used medications
(Roujeau et al., 1995). This knowledge assists physicians in
deciding which drug(s) to discontinue, especially in elderly
patients with polypharmacy. A subsequent study (Euroscar)
replicated most of the international study’s findings, adding
validity to the observed associations (Mockenhaupt et al.,
2008).
In addition to identifying drugs that may induce SCAR,
observational studies have identified characteristics of people
at increased risk for adverse drug reactions. Numerous risk
factors have been identified, such as the use of multiple
Table 2. Continued
Item no. Recommendation
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction
and magnitude of any potential bias
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results
from similar studies, and other relevant evidence
Generalizability 21 Discuss the generalizability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on
which the present article is based
Abbreviation: STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.
1Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and cross-
sectional studies.
With permission of the STROBE authors, the checklist is copied from http://www.strobe-statement.org/.
www.jidonline.org 999
T Nijsten and RS Stern
Better Understanding of Skin Disease with Epidemiology
drugs, concomitant medical conditions, and other patient
characteristics, such as lifestyle and genetic factors. A
case–control methodology was used to determine genetic
risk factors for SCAR. A striking example is a very high risk of
hypersensitivity to carbamazepine in Han Chinese with HLA
B1502 (odds ratio¼ 895) (Chung et al., 2004). The USFDA
(US Food and Drug Administration) now recommends that
Asians should be screened for this haplotype before starting
carbamazapine and that HLA B1502–positive individuals
should not be treated with carbamazapine.
THE ORIGIN OF LYME DISEASE
Unique skin findings can help focus epidemiologic studies of
diseases with noncutaneous manifestations. The expanding
red annular lesions of erythema chronicum migrans seen in
many of the originally described patients who developed an
acute relapsing arthritis in the small Connecticut town of
Lyme was key to the first epidemiologic study to identify a
tick as a vector for ‘‘Lyme Arthritis’’ (Steere et al., 1977). The
characteristic erythema chronicum migrans was essential to
the recognition that Lyme disease was not only a disease of
southern Connecticut but also a (endemic) disease affecting
patients in temperate parts of North America, Europe, and
Asia. Moreover, the cutaneous signs of Lyme disease guided
the studies that established the Borrelia burgdorferi group as
the causative infectious agents (Burgdorfer et al., 1982;
Schrock, 1982). The incidence of Lyme disease is as high as
160 cases per 100,000 and appears to be rising, but this may
be attributable to increased awareness only (Bhate and
Schwartz, 2011). There is a geographical variation of the
different Borrelia genospecies, which in turn can affect the
distribution of disseminated disease presentations.
The identification of the vector and its spirochete led
to recommendations in the primary prevention of Lyme
disease—such as avoiding exposure to ticks, using tick
repellents, wearing long-sleeved shirts, and tucking in
clothes. Secondary prevention involves daily skin inspection
for early detection and removal of ticks during summer. Early
removal is pivotal because infected ticks do not transmit
spirochetes during the first hours of a feed (up to 36 hours).
After tick removal, patients should be followed up for at least
6 weeks for clinical signs of Lyme disease, most importantly
erythema chronicum migrans. Serological screening follow-
ing a tick bite without clinical signs is controversial. Lyme
disease treatment depends on its clinical stage (I–III) and
presentation, and consists of doxycyline (or amoxicillin) and
ceftriaxone for encephalitis and carditis.
The PUVA Follow-Up Study
In 1974, oral psoralen photochemotherapy (PUVA) for
psoriasis was shown to be highly effective (Parrish et al.,
1974). However, PUVA is mutagenic, carcinogenic in
animals, and immunosuppressive, all of which are risk factors
for nonmelanoma skin cancer. In addition, PUVA simulates
melanogenesis and activates melanocytes. Pivotal to evaluat-
ing the place of PUVA in psoriasis therapy was quantification
of its carcinogenic risk. Case–control studies or controlled
clinical trials were unlikely to be practical approaches to
assessing these risks in humans. A cohort study of the first few
patients treated with PUVA at 16 centers was organized, and
these patients have been followed up for nearly 30 years.
Within 3 years of first exposure to PUVA, an increased
incidence of squamous cell carcinoma was observed in this
cohort. An association between higher exposure and
increased risk was noted (Stern et al., 1979). However, other
factors might have accounted for these observations. By
1984, the incidence of squamous cell carcinoma was greatly
increased. Analyses that accounted for likely confounding
factors demonstrated a clear relationship between increasing
exposure to PUVA and a persistent squamous cell carcinoma
risk (Stern et al., 1984a, b; Nijsten and Stern, 2003a). It was
not until 13 years later that a modest dose-related increase in
melanoma risk was documented in this cohort (Stern et al.,
1997). Because information on exposures to other therapies
for psoriasis was also quantified in this study, a nested
case–control study was able to demonstrate the carcinogenic
risks of ciclosporine in PUVA-treated patients (Marcil and
Stern, 2001). Other analyses from this study showed a modest
dose-related increase in the risk of squamous cell carcinoma
with (broad and narrow band) UVB therapy and a modest
protective effect of oral retinoids for patients who had
received PUVA (Nijsten and Stern, 2003b; Lim and Stern,
2005). These findings stimulated research into the biology of
carcinogenesis and psoriasis. The limitations of PUVA in
long-term use have also spurred efforts to develop new
treatments for psoriasis.
Isotretinoin and teratogenity
Since 1982, millions of patients have benefited from the
remarkable effectiveness of isotretinoin in the treatment of
acne. Retinoids, including isotretinoin, are teratogens. How-
ever, the magnitude of teratogenic risk in humans with
isotretinoin was unclear initially, and whether isotretinoin
was appropriately prescribed was hotly debated. Throughout
this controversy, epidemiologic studies provided objective
information on isotretinoin prescription and associated
pregnancy risks and rates.
Initially, the suspicion that isotretinoin was a human
teratogen came from spontaneous cases reported to the FDA
(Rosa, 1983). Shortly thereafter, the enhanced adverse drug
reaction reporting systems of the American Association of
Dermatology helped establish the range of malformations
associated with isotretinoin exposure during pregnancy
(Rosa, 1983). Subsequent case series established risk factors
for isotretinoin exposure during pregnancy (Dai et al., 1992).
These findings helped shape regulatory interventions in-
tended to reduce the frequency of isotretinoin exposure in
pregnancies.
Although highly regulated, the place of isotretinoin in our
therapeutic armamentarium has been established. However,
during the 1980s, some FDA officials and others advocated
even greater restrictions on isotreinoin use, and some called
for its removal. These individuals based their call for such
restrictions on their estimates of the frequency of isotretinoin-
associated birth defects (Stern, 1989) and the claim of a low
prevalence of severe acne in women. Epidemiologic analyses
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showed their estimates of pregnancy exposure to be far
higher than was likely to be the case and their claim of the
rarity of cystic scarring or severe acne in women to be
incorrect. Epidemiological analyses of a population-based
study demonstrated that the prevalence of severe acne
was substantial in both men and women (Stern, 1992). A
study of physician-based office practices also demonstrated
the high frequency of office visits for acne and that only a small
proportion of such visits included isotretinoin prescriptions.
These studies directly countered claims that severe acne was
rare and that isotretinoin was greatly overprescribed, allowing
the continued use of this highly effective drug.
Psoriasis and cardiovascular disease
Several decades ago, a cohort study suggested that the
incidence and causes of death of PUVA-treated psoriasis
patients were comparable to that of the general population
(Stern and Lange, 1988), and another cohort linkage study
observed an increased mortality rate for patients who were
ever hospitalized for their psoriasis compared with people
without psoriasis, which was in part attributed to smoking
and alcohol consumption (Poikolainen et al., 1999). In the
same period (initiated by case series describing how psoriasis
of patients vanished while using ciclosporine for other
reasons; Mueller and Herrmann, 1979), it became clear that
psoriasis was an immune-mediated disease. Cutaneous
activated T lymphocytes and dendritic cells were abundant,
but the findings of cross-sectional, case–control, and cohort
studies investigating serological markers of systemic inflam-
mation induced by psoriasis were inconsistent. In accordance
with psoriasis, inflammation appeared to have a key role in
the pathogenesis of many diseases, including atherosclerosis,
diabetes, and obesity. In their landmark cohort study
including data from primary physicians in the United
Kingdom, Gelfand et al. (2006) explained the observed
increased risk of acute myocardial infarction among psoriasis
patients from a large primary physician database due to
elevated systemic inflammation. This study inspired many
other studies, of which most, but not all, confirmed the
association between psoriasis and other comorbidities.
However, the majority of these studies used existing
databases that were designed for other research objectives
and lacked information about important confounders (e.g.,
obesity, smoking, physical activity, psychological health, and
health-care consumption) that could have explained (in part)
the association between psoriasis and cardiovascular disease
(Nijsten and Wakkee, 2009). To make it even more
complicated, other observational research has suggested that
risk factors for acute myocardial infarction, such as smoking
and obesity, induce psoriasis onset—illustrating the difficulty
of incorporating temporal relationships in this type of
research (Naldi et al., 2005; Setty et al., 2007). Although
the possible increased acute myocardial infarction risk of
psoriasis patients is important, cautious interpretation of the
data remains pivotal, and treatment guidelines should not be
adjusted in the absence of high-quality observational and
interventional studies. The hypothesis that psoriasis is a
systemic disease is interesting, but it is not clear yet whether
the observed associations are directly related to psoriasis or
indirectly related to the effect of psoriasis on a patient’s
lifestyle and vice versa.
FUTURE DIRECTIONS OF DERMATOEPIDEMIOLOGY
Most of the straightforward questions have been answered by
inductive approaches that relate a single risk factor to a single
outcome. The real challenge for epidemiology is whether it
can assist in a better understanding of complex processes and
diseases (Ness et al., 2009). On a global level, we are facing
unprecedented health challenges such as inequalities, emerg-
ing infections, climate change, epidemics of ‘‘modern’’
diseases, and aging populations, which require the involve-
ment of epidemiologists. On a disease level, the challenge
lies in the understanding of common complex diseases that
are associated with multiple (unknown) genes that usually
interact with various and often changing environmental
factors. Understanding the epidemiological aspects of these
diseases requires large sample sizes, sophisticated statistical
techniques, and the availability of genetic data and biological
specimens, emphasizing the importance of large population-
based cohorts and biobanks that may form international
research consortia. In the face of these challenges, the
European and American Dermato-Epidemiology Networks
(EDEN and ADEN, respectively) should further strengthen
their international research efforts in order to take significant
epidemiological steps forward.
The future of epidemiology demands collaborative re-
search across disciplines, institutions, and countries, as
demonstrated by genetic epidemiological studies, clinical
trial networks, and pharmacovigilance studies. More than
ever, epidemiologists will have to be dynamic team players
with a variety of methodological skills in order to address the
highly complex unresolved questions that face us.
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